What is NAD⁺ IV therapy, including its purpose, dosing, safety, and evidence?

What is NAD+ IV Therapy?

NAD+ IV therapy is an unproven commercial intervention that lacks FDA approval for therapeutic medical use, has no published randomized controlled trials in humans, and should not be recommended outside of research protocols—patients seeking NAD+ repletion should instead use oral niacin precursors, which have established safety data and effectively increase blood NAD+ levels. 1

Current Regulatory Status and Evidence Base

• The FDA labeling for intravenous NAD+ lists only cosmetic applications, not therapeutic medical indications 1
• No published randomized controlled trials exist for NAD+ infusions in humans in medical databases 1
• NAD+ is a large, charged molecule with poor bioavailability and stability when injected intramuscularly or intravenously 1
• One FDA-listed product (Viatrexx-NAD+) is labeled "For Oral Use" as a homeopathic preparation, not as an IV therapeutic 2

What Proponents Claim vs. What Evidence Shows

Marketing claims suggest NAD+ IV therapy treats aging, neurodegenerative diseases, substance use disorders, and metabolic conditions. However:

• While one small randomized trial (n=180) in ischemic cardiomyopathy showed improved LVEF with 10 mg/day IV NAD+ for 7 days 3, this represents a single study in a specific cardiac population and does not support broad therapeutic claims
• A pilot study in substance use disorder (n=50) showed reduced cravings but lacked placebo controls and blinding 4
• Pharmacokinetic data reveal that at infusion rates of 3 μmol/min, NAD+ is rapidly and completely removed from plasma for at least 2 hours, with metabolism consistent with NAD+ glycohydrolase activity 5

Tolerability and Safety Concerns

NAD+ IV infusions cause significant adverse effects that prolong administration time:

• Participants receiving 500 mg NAD+ IV reported moderate to severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusions 6
• Average infusion time for NAD+ IV was 97 minutes versus 37 minutes for nicotinamide riboside IV due to symptom severity 6
• High doses of nicotinic acid can cause flushing, nausea, vomiting, liver toxicity, blurred vision, and impaired glucose tolerance 1
• Flushing effects occur at doses as low as 30 mg/day for free nicotinic acid 1

Guideline-Recommended Alternatives

The American Society for Parenteral and Enteral Nutrition recommends the oral/enteral route for niacin supplementation whenever the gastrointestinal tract is functional 1:

• Daily niacin intake recommendations: 16 mg/day for adult males, 14 mg/day for adult females 1
• For patients requiring parenteral nutrition due to non-functional GI tract, standard niacin at 40 mg/day is recommended, not injectable NAD+ 1
• The upper safety limit for nicotinamide is approximately 900 mg/day for adults (12.5 mg/kg body weight/day) 1

Clinical Algorithm for Patient Requests

When patients inquire about NAD+ IV therapy:

1. Assess for true niacin deficiency by evaluating risk factors: corn-based diet, malnutrition, chronic alcoholism, malabsorption states 1
2. Screen for pellagra symptoms (the "3 Ds": diarrhea, dermatitis, dementia) 1
3. Recommend dietary sources first: fortified packaged foods, meat and poultry, red fish (tuna, salmon), nuts, legumes, and seeds 1
4. If supplementation is needed, use oral nicotinamide (300 mg/day for pellagra treatment) or nicotinic acid (15-20 mg/day) 7
5. Do not prescribe NAD+ infusions for therapeutic purposes outside of research protocols due to lack of guideline support, poor pharmacokinetics, and absent proven clinical benefit 1

Oral NAD+ Precursors: Evidence-Based Options

Oral NAD+ precursors have distinct safety profiles and evidence bases:

• Nicotinic acid can lower LDL cholesterol by several percentage points at therapeutic doses and is recognized by the American Heart Association for patients with triglycerides 200-499 mg/dL and low HDL-C 8
• The American Diabetes Association recommends monitoring liver function tests every 3 months when using nicotinic acid due to hepatotoxicity risk with sustained-release formulations 8
• Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are newer oral precursors under investigation, with the most common side effects being gastrointestinal symptoms 1

Key Clinical Pitfalls to Avoid

• Do not assume injectable NAD+ is superior to oral precursors—no evidence supports this claim 1
• Do not confuse niacin precursors with direct NAD+ administration—they have different safety profiles and evidence bases 1
• Do not recommend NAD+ injections based on marketing claims—they lack regulatory approval for therapeutic use 1
• Do not use nicotinic acid forms without warning patients about flushing at doses as low as 30 mg 1